Get the Stockscreener App
48.71
6.09%
-3.16
After Hours:
48.55
-0.16
-0.33%
Moderna Inc stock is traded at $48.71, with a volume of 19.86M.
It is down -6.09% in the last 24 hours and up +50.85% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$51.87
Open:
$49.812
24h Volume:
19.86M
Relative Volume:
1.67
Market Cap:
$19.03B
Revenue:
$3.14B
Net Income/Loss:
$-3.36B
P/E Ratio:
-5.5796
EPS:
-8.73
Net Cash Flow:
$-4.03B
1W Performance:
+16.45%
1M Performance:
+50.85%
6M Performance:
+40.50%
1Y Performance:
+14.91%
1-Day Range:
$46.84
$50.41
1-Week Range:
$40.70
$55.20
52-Week Range:
$22.28
$55.20
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
48.71 | 20.27B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.41 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.55 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
814.74 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
357.98 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.32 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Moderna Options Spot-On: On January 23rd, 191.29K Contracts Were Traded, With 974.59K Open Interest - Futubull
The Globe’s stars and dogs for the week - The Globe and Mail
Moderna's Growth Strategy Seen as Reassuring Investors -- Market Talk - Futubull
Promising Biotech Stocks Worth WatchingJanuary 23rd - MarketBeat
Moderna (NASDAQ:MRNA) Shares Gap DownHere's What Happened - MarketBeat
Lipid Nanoparticle Manufacturing Market: An 18.9% CAGR Market Driven by Nucleic Acid Therapies - GlobeNewswire Inc.
Moderna Won’t Run Phase III Vaccine Trials as Skepticism Grows in US: Bloomberg - BioSpace
Analyst recommendations: Amgen, P&G, Spotify, Duolingo, Moderna… - marketscreener.com
Moderna (MRNA) stock jumps after-hours as CEO signals pullback in new vaccine trials - TechStock²
Intel, GE Aerospace, Moderna, Abbott, Mobileye, McCormick, and More Stock Movers - Barron's
Moderna (NASDAQ:MRNA) Trading Up 10.2%Time to Buy? - MarketBeat
Moderna Stock Soars. Why a Cancer Vaccine Study Has Sparked a Rally. - Barron's
Moderna and Merck Solidify Oncology Leadership as Five-Year Melanoma Data Fuels Market Rally - FinancialContent
Moderna (MRNA) Halts Phase 3 Vaccine Development Amid U.S. Regulatory Challenges - GuruFocus
Moderna (MRNA) Sees Bullish Activity with Increased Options Trading - GuruFocus
Moderna cutting R&D on vaccines amid U.S. pushback: CEO (MRNA) - Seeking Alpha
Moderna curbing investments in vaccine trials due to US backlash, CEO tells Bloomberg TV - kfgo.com
Moderna-Merck mRNA Vaccine Slashes Melanoma Recurrence by 49% at 5 Years - WebProNews
Biotech Stocks To Keep An Eye OnJanuary 22nd - MarketBeat
Intel, GE Aerospace, Moderna, Abbott, Arista, Mobileye, McCormick, and More Movers - Barron's
Moderna (MRNA) Stock Surge Boosts ETFs with High Exposure - GuruFocus
Moderna (MRNA) Surges Over 20% This Week, Hits 52-Week High - GuruFocus
MRNA & MRK's Personalized Cancer Therapy Delivers Strong 5-Year Data - Yahoo Finance
Moderna (MRNA) CEO Cites U.S. Vaccine Opposition as Barrier to New Trials - GuruFocus
Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melano - pnj.com
Moderna is curbing investment in vaccine trials due to US backlash - bostonglobe.com
Moderna’s rally ripples through biotech and health care ETFs - Seeking Alpha
Moderna (MRNA) Surges Amid Market Gains - GuruFocus
Moderna shares soar through the week, momentum data points toward caution - MSN
Moderna extends rally on positive cancer vaccine results - Sherwood News
Moderna’s 2026 Pivot: From Pandemic Pioneer to Oncology Powerhouse - FinancialContent
Moderna Stock Explodes To New 52-Week High: What's Driving The Action? - Benzinga
Moderna shares soar through the week, momentum data points toward caution (MRNA:NASDAQ) - Seeking Alpha
Moderna Is Curbing Investment in Vaccine Trials Due to US Backlash - Bloomberg
Moderna extends YTD rally to hit 52-week high (MRNA:NASDAQ) - Seeking Alpha
Moderna’s Breakthroughs Push Stock Trends into New Heights - StocksToTrade
What's Happening With Moderna Stock? - Forbes
Buy or Sell Moderna Stock At $50? - Trefis
Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Rise As BEA Pegs Q3 GDP At 4.4%— Microsoft, Moderna, Intel In Focus (UPDATED) - Benzinga
These Stocks Are Today’s Movers: Moderna, Intel, GE Aerospace, Abbott, Micron, Mobileye, Venture Global, and More - Barron's
Moderna (MRNA) Touches 52-Week High on Strong Clinical Results - Finviz
Moderna (MRNA) Stock Climbs 16% on Melanoma Vaccine Breakthrough - Blockonomi
Moderna, Intel, GameStop, Micron, Venture Global, and More Stock Market Movers - Barron's
Stock market today: S&P 500, Dow Jones futures rise as Trump scales down EU tariff threats—Microsoft, Moderna, Intel in focus - MSN
Moderna Stock Is Surging. Why a Cancer Vaccine Study Has Sparked a Rally. - Barron's
Moderna extends rally after drug-trial results, and other early market movers - MarketWatch
Trending tickers: AMD, Intel, Moderna, Associated British Foods and Young & Co's Brewery - Yahoo Finance UK
Moderna (MRNA) Stock: Melanoma Vaccine Data Pushes Shares to 52-Week High - CoinCentral
Moderna Inc.: From Pandemic Breakout Star to Platform Powerhouse - AD HOC NEWS
Moderna Stock Soars 16%, Hits 52-Week High as "mRNA 2.0" Cancer Vaccine Data Stuns Markets - FXLeaders
Analysts Favor Novavax Over Moderna After $30M Pfizer Licensing Deal - Intellectia AI
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.92%
2.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):